1177 results about "Secretion" patented technology

The invention belongs to the technical field of microorganisms, and relates to high-activity plant lactobacillus KL100 for relieving anxiety and depression and application of the high-activity plant lactobacillus KL100. The plant lactobacillus provided by the invention is KL100, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.27192, and is classified and named as the plant lactobacillus. The plant lactobacillus is KL100, has a good gastrointestinal passing rate, shows a breeding characteristic in the stomach after being embedded, is improved in cholate-resistant survival rate, and can be used for preparing the plant lactobacillus. According to the application disclosed by the invention, the expression of IL-1beta and TNF-alpha in a mouse body can be effectively reduced, the expression of IL-10 can be improved, and the secretion of 5-hydroxytryptamine by chromaffin cells in intestinal tracts can be promoted, so that anxiety and depression can be relieved, the strain resource is expanded, the development of the biological medicine field is promoted, and a new direction is provided for treating anxiety and depression.

The invention discloses a toxoplasma gondii attenuated strain as well as a construction method and application thereof. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 disclosed by the invention is obtained by knocking out MIC1 and MIC3 genes from a TIR1 strain by utilizing a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 can effectively enhance macrophage functions including phagocytic ability, proinflammatory factor secretion and the like, and provides theoretical basis and technical support for clarification of an immunoregulation network of toxoplasma gondii-host interaction and development of vaccine design based on attenuated strains.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.

The invention belongs to the field of biological medicines, and discloses an application of a stem cell extract in lysosome and mitochondrial related diseases, a preparation method of the stem cell extract comprises the following steps: S1) culturing mesenchymal stem cells and creating stress conditions to stimulate the mesenchymal stem cells; and S2) separating and purifying the culture supernatant of the mesenchymal stem cells cultured in the step S1) to obtain the stem cell extract, wherein S21) the culture supernatant is filtered to obtain a filtrate; s22) performing 3KD ultrafiltration concentration on the filtrate to obtain a crude sample; s23) purifying the crude sample by using molecular sieve exclusion chromatography or reversed-phase chromatography to prepare a purified sample; in molecular sieve exclusion chromatography, by taking the volume of the eluent as a reference, collecting the 10th to 40th mL of eluent, namely a purified sample; and S24) taking the purified sample to form a preparation. According to the application, the culture supernatant containing stress stem cell secretions is taken through stress culture of stem cells, and a purification method is combined, so that the prepared preparation can be used for treating lysosome and mitochondrial related diseases.

The invention belongs to the technical field of stem cell culture and exosome extraction, and provides an RELM beta pre-activated stem cell outer vesicle with high anti-inflammatory and anti-fibrosis activity. According to the method, the mesenchymal stem cells are subjected to hunger culture after being adhered to the wall and then are continuously cultured by a complete culture medium containing RELM beta factors, then supernate is collected, and the exovesicles are obtained through separation. In the preparation process of the extracellular vesicles, the paracrine function of MSC cells is promoted by the RELM beta, the secretion of anti-inflammatory and anti-fibrosis active factors is obviously activated, and the generation of the extracellular vesicles with enhanced anti-inflammatory and anti-fibrosis effects is promoted. Gene modification is not involved, toxic biochemical reagents or materials are not added, exogenous operation steps are simple and convenient, clinical application is guaranteed through sterile operation, no RELM beta residues exist after extracellular vesicle extraction, and the method is safe, non-toxic and effective.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention belongs to the field of biological medicine, and discloses an oral flora marker related to tongue squamous cell carcinoma (TSCC) and application of the oral flora marker. The oral cavity flora marker is Stomatobacterium longum (SBL), and the oral cavity flora marker is SBL (Stomatobacterium longum); the invention further discloses a diagnostic product of the TSCC, application of the SBL in preparation of a medicine for treating the TSCC and the medicine for treating the TSCC. The diagnosis product prepared by taking the SBL as the marker can quickly and effectively carry out early diagnosis on the TSCC so as to achieve the purposes of early discovery, early treatment and improvement of the survival rate. The medicine provided by the invention can specifically inhibit the SBL from secreting the nano extracellular vesicles so as to inhibit the expression of BRCA1 and further inhibit the expression of EXO1 and TP53BP1, so that the proliferation and cell cycle progress of TSCC cells are inhibited, and the treatment on the TSCC is realized. The medicine has good specificity and can be used for effectively treating TSCC.

The present application relates to the technical field of oat bran deep processing, and particularly relates to an oat active polypeptide with GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity, and a preparation method and application thereof.The present application is prepared by adding alkaline protease and ficin for double-enzyme step-by-step hydrolysis after homogenate, enzymolysis and alkali extraction and acid precipitation pretreatment, and then filtering, ultrafiltration desalination and drying, so that the oat active polypeptide with GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity is obtained.The present application is simple to operate, low in equipment requirement, and suitable for industrial large-scale production.The prepared oat active polypeptide has GLP-1 secretion promotion, blood sugar reduction and lipid reduction activity, has a significant inhibitory effect on pancreatic lipase and alpha-glucosidase, has an obvious GLP-1 secretion promotion effect, and has a significant blood sugar reduction and lipid reduction effect.

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

The invention discloses a method for increasing the yield of mesenchymal stem cell exosomes. A main culture medium used in the method is a human umbilical cord mesenchymal stem cell serum-free culture medium, and different natural compounds are respectively added in three main stages of mesenchymal stem cell growth, namely a recovery stage, an amplification stage and a stable stage, so that the characteristics of the mesenchymal stem cells in the stages are pertinently improved; the survival rate of the mesenchymal stem cells is protected in stages, the amplification efficiency of the mesenchymal stem cells is improved, the stability of the mesenchymal stem cells is maintained, and the exosome secretion amount of the mesenchymal stem cells can be remarkably increased through combined use of the three natural compounds. According to the invention, the secretion amount of the exosome of the mesenchymal stem cells can be obviously increased, and the problem of low yield of the mesenchymal stem cells at present is solved.

The invention discloses a fish by-product active peptide, a preparation and application, and belongs to the technical field of biological active peptides. The amino acid sequences of the fish by-product active peptide are shown as SEQ ID NO: 1 to SEQ ID NO: 3. Both the single peptide fragment and the compound peptide fragment of the fish by-product active peptide can obviously inhibit NO secretion of a lipopolysaccharide (LPS)-induced macrophage (RAW264.7) inflammation model, so that the fish by-product active peptide has a relatively good application prospect in preparation of a product with an anti-inflammatory effect; and a foundation is laid for high-added-value utilization of salmon byproducts and promotion of research, development and application of functional active peptides.

The present invention relates to the field of stem cell technology. The present invention discloses a method for inducing stem cells to secrete specific factors, which includes stimulating stem cells with high-frequency waves, emitting sound waves of a specific frequency to stem cells, regulating stem cells in a hypoxic environment, culturing stem cells in a hypoxic environment, stimulating stem cells with oxidative stress, and subjecting stem cells to oxidative stimulation treatment. The present invention can significantly enhance the proliferation ability of stem cells, promote the secretion of multiple active factors, and improve cell function and adaptability. As a non-invasive physical method, high-frequency wave stimulation can activate internal cell signal pathways without introducing exogenous substances, significantly improving the proliferation ability and tissue repair potential of stem cells. Hypoxic environment regulation simulates the naturally existing microenvironmental conditions in the body, greatly promoting the secretion of active factors such as vascular endothelial growth factor, basic fibroblast growth factor, and brain-derived neurotrophic factor for tissue repair and immune regulation.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

Disclosed herein are modified strains for improving secretion of recombinantly expressed products secreted from a host organism with improved growth and productivity characteristics, as well as methods of using the modified strains.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

The invention belongs to the technical field of active peptide preparation, and particularly relates to an active collagen peptide with an immunoregulation function and a preparation method and application thereof. The active collagen peptide with an immunoregulation function is prepared by using a method of performing composite enzymolysis and separating and collecting specified collection liquid by using a chromatographic column, and a new thought is provided for improving the immunity; the prepared active collagen peptide can significantly improve the proliferative activity, phagocytic ability and NO secretion amount of RAW264.7 cells and change the cell morphology, has an important regulation effect on immune balance recovery of immunosuppression model mice, and can regulate the problem of low immunologic function of mice induced by cyclophosphamide, regulate immune balance and improve the body immunity.

The invention discloses recombinant streptomyces mobaraensis as well as a construction method and application thereof, and belongs to the technical field of bioengineering. According to the invention, smY2019 is used as an original strain, and a CRISPR / cas9 technology is utilized to construct five chassis cells of a GIs gene cluster; on the basis of smY2019-deltaG5, two kinds of chassis cells in which endogenous CRISPR / Cas system genes are knocked out are constructed. And on the basis of the smY2019-deltaG5-C2, further constructing a chassis cell smY2019-deltaG5-C3 of which a non-homologous end connection (NHEJ) repair pathway gene is knocked out. The TGase secretory enzyme activity of the chassis cell smY2019-deltaG5-C3 is improved by 37.3% compared with that of the original strain smY2019, and meanwhile, the transformation efficiency, the growth speed, the protein synthesis capability and the energy metabolism level of the chassis cell are obviously improved compared with that of the original strain smY2019.

The invention discloses a grape seed source anti-inflammatory peptide, and belongs to the technical field of biological medicine. The amino acid sequence of the anti-inflammatory peptide is selected from any one of WGF, SHFGF, EGPFF, WAPR, SFYRAF, HFAFL, PGRF or FDSF. A BPS-induced RAW 264.7 mouse mononuclear macrophage inflammation model is established, and the eight synthetic peptides are found to significantly reduce the content level of NO in inflammatory cells and have an inhibition effect on secretion of inflammatory factors TNF-alpha and IL-6. A qRT-PCR (quantitative reverse transcription-polymerase chain reaction) experiment shows that the synthetic peptide can inhibit expression of mRNA (messenger Ribonucleic Acid) of p65, Tnf alpha, Il6, Il1b and Nos2, and can play an anti-inflammatory role by regulating and controlling an NF-kappa B signal channel. According to the method, the high-activity anti-inflammatory peptide is screened from the wine brewing byproduct grape seeds for the first time, and green and high-value utilization of the grape processing byproduct is realized.

The invention discloses bacillus subtilis capable of producing cellulase at high yield and application of the bacillus subtilis, and belongs to the technical field of biology, the bacillus subtilis is classified and named as bacillus subtilis KC7-2, the bacillus subtilis KC7-2 is preserved in China Center for Type Culture Collection on July 15, 2024, and the preservation number is CCTCC NO: M20241570. The bacillus subtilis provided by the invention shows excellent performance in the aspect of secretion of cellulase and hemicellulase, especially reaches an enzymatic activity peak in the early growth stage (24h) of a strain, and can maintain a certain level of enzymatic activity for a long time later. Due to the characteristics, the strain has important application value in the fields of forage feed improvement, biomass degradation, environmental protection and the like.

The invention provides a plant lactobacillus pentosus for promoting cellular immunoregulation as well as application and a product thereof, and belongs to the field of microorganisms. The preservation number of the provided lactobacillus pentosus is CGMCC (China General Microbiological Culture Collection Center) No.32858, and the lactobacillus pentosus is preserved in the China General Microbiological Culture Collection Center on November 29, 2024. The strain provided by the invention can promote macrophages to secrete TNF-alpha, IL-10 and IL-1beta in a normal state and down-regulate the secretion of NO, and meanwhile, the thermally inactivated strain also has the effect of promoting the macrophages to secrete TNF-alpha, and can further intervene in the secretion of TNF-alpha, IL-10 and IL-1beta in a macrophage inflammation state; in a Caco-2 cell-macrophage co-culture system and a mouse primary epithelial cell-splenic lymphocyte co-culture system, a promotion effect is also shown.

The invention discloses an active exosome stent coating based on traditional Chinese medicine enhanced secretion promotion and a preparation method and application thereof, and belongs to the technical field of biological medicine and interventional instruments. The stent coating comprises exosomes, wherein the exosomes comprise myocardial cell active exosomes and human mesenchymal stem cell active exosomes which are intensified and secreted by traditional Chinese medicines; wherein the traditional Chinese medicines comprise placenta extract, pilose antler extract, sheep myocardial peptide, sea cucumber peptide, lycium ruthenicum peptide, cnidium lactone, curculigo orchioides extract and morinda officinalis extract; the intervention concentration of each component added into cells is 2-50 [mu] g / mL; the light-cured gel matrix is prepared from methacrylated gelatin, a photoinitiator and polyether 127; tacrolimus; the final concentration of the exosome is 1 * 10 < 9 >-12 * 10 < 9 > particles / mL, and the final concentration of the tacrolimus is 5-25 mu g / mL. The coating can be coated on the surface of the poly-L-lactic acid degradable stent to prepare the degradable stent, and has obvious vascular repair promoting capability.

The invention discloses application of an SFRP1 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, SFRP1 is taken as a research object, an SFRP1 overexpression vector or siRNA-SFRP1 is respectively transfected to ovarian granular cells by constructing the SFRP1 overexpression vector and synthesizing small interfering RNA (siRNA-SFRP1), then changes of signal channel gene mRNA and protein level related to ovarian granular cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granular cells are detected. Results show that the SFRP1 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. The application of the SFRP1 in the ovarian granular cells is explored, and the SFRP1 has good application in research of an ovarian follicle atresia mechanism, initial estrus initiation and the like.

The invention relates to the technical field of biology, in particular to application of CD200 in evaluation of biological functions of mesenchymal stem cells. The biological efficacy of the cells can be rapidly judged by detecting the positive rate and the average fluorescence intensity of the CD200 on the surfaces of the mesenchymal stem cells through flow cytometry, and the method is simple, convenient and rapid, has a wide application prospect and is worthy of popularization and application. According to the invention, the expression level of the CD200 on the surface of the mesenchymal stem cell and the biologic function (secretion level of anti-inflammatory factors PGE2 and IDO, and inhibition rate on TNF-alpha and IFN-gamma secreted by PBMC) of the CD200 are illuminated for the first time, and the biological function of the umbilical cord mesenchymal stem cell is evaluated by adopting a method for detecting the positive rate of the CD200 and MFI for the first time. When the CD200 positive rate is greater than 40% and the average fluorescence intensity MFI is greater than 500, the TNF alpha secretion inhibition rate is greater than 40%, and the IFN gamma secretion inhibition rate is greater than 20%.

The invention discloses an induction culture medium for preparing human umbilical cord mesenchymal stem cell exosomes and application of the induction culture medium, and relates to the technical field of exosome culture. The additive is prepared from the following components: 0.8 to 1.5 percent of ITS, 0.03 to 0.05 percent of a luteolin extract, 0.04 to 0.06 percent of a herba taraxaci extract, 0.02 to 0.04 percent of a radix ginseng extract, 0.03 to 0.05 percent of resveratrol, 0.01 to 0.03 percent of vitamin C, 0.03 to 0.05 percent of a pimpinella thellungiana extract, 0.01 to 0.03 percent of a rhizoma dioscoreae extract and 0.01 to 0.02 percent of sodium citrate; the induction culture medium provided by the invention not only can avoid introduction of exogenous substances and reduce the pollution risk, but also can promote proliferation of stem cells and effectively induce synthesis and exosome secretion of a large number of human umbilical cord mesenchymal stem cells.

Provided are a cat allergen polypeptide fragment and use thereof. Fel d1 is divided into a plurality of polypeptides of 10-20 amino acids, which are then co-expressed with VLPs proteins; subsequently, hyperimmune serum of Fel d1 is used for screening; and 2 Fel d1 polypeptides with relatively good immunogenicity are successfully screened. The 2 polypeptides are used for co-expression with VLPs and then formulated into a vaccine to immunize a cat. The secretion amount of Fel d1 in the cat saliva is detected, and the secretion amount of Fel d1 can be reduced by 80% or more. The described polypeptides effectively reduce the secretion amount of the Fel d1 protein in the cat saliva, and reduce the spread of Fel / d1 in the air.

The invention provides a nanogel for rapid permeation of articular cartilage and responsive release of a growth factor, which is prepared by polymerizing a peptide fragment which can be cut by a substance (mainly enzyme) which can be specifically expressed on the surface of osteoarthritis cells or secreted into a matrix with the growth factor, an acrylamide monomer and a cationic micromolecule monomer. Unreacted monomer molecules are filtered out through an ultrafiltration tube or other filtering systems, so that the nanogel which can rapidly permeate into the deep part of articular cartilage and can be recognized and cut by enzyme highly expressed on the surface of osteoarthritis cells or secreted enzyme to release growth factors is prepared, and the effect of the growth factors can be more effectively exerted; the nanogel has strong cartilage infiltration capacity, can completely infiltrate cartilage with the thickness of 1mm within less than 3 days, can be cut by MT1-MMP protein specifically expressed on the surfaces of osteoarthritis cells, releases growth factors, is specifically combined with growth factor receptors on the surfaces of cartilage cells, and activates downstream signal channels, so that the proliferation of the cartilage cells is promoted, and the cartilage cell proliferation rate is increased. The cartilage matrix secretion is promoted, so that the cartilage matrix thickening effect is realized, and the osteoarthritis is prevented and treated.

The invention belongs to the field of biotechnology and environmental governance, and particularly relates to a manganese peroxidase mutant based on high-throughput screening modification and application of the manganese peroxidase mutant to straw degradation. Aiming at the problems of low natural secretion amount, insufficient specific activity, complex preparation process and the like of the existing manganese peroxidase, the method comprises the following steps: firstly, constructing engineering bacteria based on an escherichia coli exocrine system, constructing a mutant library through error-prone PCR in combination with a directed evolution technology, and performing high-throughput screening by utilizing an ABTS colorimetric method; the recombinant manganese peroxidase mutant with high catalytic activity is obtained, and the enzyme activity is improved by 1.29 times compared with that of a wild type. Furthermore, recombinant engineering bacteria are constructed on the basis of a bacillus subtilis exocrine system, and efficient secretion of the mutant enzyme is achieved. The mutant enzyme preparation is used for wheat straw degradation, and the lignin degradation rate reaches 41.37% (improved by 30.09% compared with that of a wild type). The method is simple and convenient in process, low in cost and remarkable in effect, and has a wide industrial application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to application of garlic polysaccharide in preparation of a product for repairing intestinal injury caused by constipation. An embodiment verifies that the garlic polysaccharide can effectively repair intestinal physical, chemical and immune barrier injuries caused by constipation, and by up-regulating expression of tight junction proteins (such as ZO-1 and Occludin) and reducing expression of Claudin-1, the garlic polysaccharide can enhance tight junction between intestinal epithelial cells and reduce intestinal permeability; besides, the garlic polysaccharide can promote secretion of intestinal mucoprotein and enhance the protection function of the intestinal mucous layer by up-regulating expression of MUC2 and MUC4 genes. The invention discloses a multi-aspect action mechanism of the garlic polysaccharide in repairing intestinal injury caused by constipation, and the garlic polysaccharide is expected to become a novel intestinal repairing agent for treating constipation and related complications thereof.

The invention discloses an application of lactobacillus mucosa LMSJ001 or a metabolite agmatine of the lactobacillus mucosa LMSJ001 in preparation of a medicine for improving intestinal aging, and the application research of the lactobacillus mucosa LMSJ001 in a constructed aging mouse model finds that the lactobacillus mucosa LMSJ001 can be used for preparing a medicine for improving intestinal aging. Therapeutic gavage and application of Lactobacillus mucosa LMSJ001 in colon organs for intervention can significantly improve aging indexes, alleviate histological aging performance, promote intestinal peristalsis of aged mice, reduce secretion of inflammatory factors of the aged mice, improve intestinal epithelial barrier functions of the aged mice and improve intestinal dryness of the aged mice. The lactobacillus mucosa LMSJ001 can generate a metabolite agmatine through arginine decarboxylase, and agmatine can improve related indexes of proliferation and differentiation of intestinal stem cells and reduce expression of related indexes of senescence. Based on the unique functions, the lactobacillus mucosa LMSJ001 or the metabolite agmatine of the lactobacillus mucosa LMSJ001 can be cooperated or complemented with other means, is used for preparing pharmaceutical compositions or detection kits and the like, and has very wide application prospects.